Ultragenyx drug apazunersen misses main goal in late-stage trial
Ultragenyx Pharmaceutical said its experimental apazunersen for Angelman syndrome did not meet the main goal in a late-stage trial, sending shares down 40% in after-hours trading.
Ultragenyx Pharmaceutical NASDAQ:RARE said on Wednesday its experimental drug for a rare genetic neurodevelopmental disorder did not meet the main goal in a late-stage trial, sending its shares down 40% in aftermarket trading.The drug, apazunersen, was tested as a treatment for Angelman syndrome, a…